Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation, according to a report released yesterday by AARP’s Public Policy Institute.
 
“Increases in the retail price of brand name prescription drugs have a corresponding impact on the cost of therapy for the individual and for all other payers,” the authors note. “In 2020, the average cost of therapy for a brand name prescription drug, based on the market basket in this study, was $6,600 per year.”
 
A second AARP PPI analysis found that Medicare Part D spent nearly $40 billion more on 50 top brand-name drugs between 2015 and 2019 because drug price increases exceeded inflation.

 

Related News Articles

Headline
The Campaign for Sustainable Rx Pricing (CSRxP), of which the AHA is a founding member, today launched new television and digital advertising encouraging…
Headline
House Energy and Commerce Committee Chairman Frank Pallone Jr., D-NJ, today re-introduced the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) with…
Headline
The Campaign for Sustainable Rx Pricing today launched a grassroots and digital advertising campaign urging policymakers to lower prescription drug prices…
Blog
The availability of swift, accurate and reliable diagnostic testing during the public health emergency has been extremely important. Lab testing is essential…
Headline
The AHA and American Society of Health-System Pharmacists today urged the Food and Drug Administration to take appropriate enforcement action to protect…
Headline
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs…